


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years ID6510

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
ALK-Abello (12 SQ-HDM SLIT,	All Wales Therapeutics and Toxicology
Acarizax)	Centre
, , , , , , , , , , , , , , , , , , , ,	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Allergy UK	Wales
Anaphylaxis UK	British National Formulary
Asthma Relief Charity	Care Quality Commission
Asthma + Lung UK	Department of Health - Northern Ireland
Asthma Trust for Asthmatic Children	Healthcare Improvement Scotland
NARA – The Breathing Charity	Medicines and Healthcare products
Sinus UK	Regulatory Agency
SmellTaste	 National Association of Primary Care
South Asian Health Foundation	
	National Pharmacy AssociationNHS Confederation
Specialised Healthcare Alliance The Country's Consists.	
The Samter's Society	NHS Wales Joint Commissioning
Healtheare professional groups	Committee Scottish Medicines Consortium
Healthcare professional groups	
Association of Respiratory Nurse Specialists	Welsh Government
SpecialistsAssociation for Respiratory	Descible comparator companies
 Association for Respiratory Technology and Physiology 	Possible comparator companies None
Division of the second	• None
	Relevant research groups
	Asthma, Allergy and Inflammation
British Society for Allergy & Clinical Immunology	Research Trust
Immunology	
British Thoracic SocietyENT UK	 British Association for Lung Research Cochrane Airways Group
	David Hide Asthma and Allergy
National Heart and Lung Institute National Heart and Description	Research Centre
Neonatal and Paediatric Pharmacists Croup	0
Group	1 NDO 011 1 T 1 1 1 11
Primary Care Respiratory Society UK Payer Callage of Capacity Prostitionary	
Royal College of General Practitioners Payer College of Nursing	National Institute for Health Research
Royal College of Nursing Payer College of Payer in the St. Child. Only the College of Payer in the St. Child. Only the College of Nursing Only the College of Nursing	Associated Public Health groups
Royal College of Paediatrics & Child	Associated Public Health groups • Public Health Wales
Health	■ Fublic Health Wales



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association 	UK Health Security Agency
<u>Others</u>	
Department of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.


The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example,





the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.